A molecular compound developed by Saint Louis University scientists restored learning, memory and appropriate behavior in a mouse model of Alzheimer’s disease, according to findings in the May issue of the Journal of Alzheimer’s Disease.
The molecule also reduced inflammation in the part of the brain responsible for learning and memory.
The paper, authored by a team of scientists led by Susan Farr, Ph.D., research professor of geriatrics at Saint Louis University, is the second mouse study that supports the potential therapeutic value of an antisense compound in treating Alzheimer’s disease in humans.
“It reversed learning and memory deficits and brain inflammation in mice that are genetically engineered to model Alzheimer’s disease,” Farr said. “Our current findings suggest that the compound, which is called antisense oligonucleotide (OL-1), is a potential treatment for Alzheimer’s disease.”
Farr cautioned that the experiment was conducted in a mouse model. Like any drug, before an antisense compound could be tested in human clinical trials, toxicity tests need to be completed.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- New Alzheimer's Treatment: Researchers Discover How Flickering Lights Might Workon February 28, 2020 at 12:00 am
> 5 million Americans of all ages suffer from Alzheimer’s disease. Since there isn’t a cure yet, medication and other management strategies have been sought-after Although Alzheimer’s predominantly ...
- CT woman says caregiving for her wife with Alzheimer’s has become a ‘labor of love’on February 27, 2020 at 5:50 pm
CONNECTICUT (WTNH) — Receiving an Alzheimer’s diagnosis not only affects the patient but the family, especially the person taking over as caregiver. It’s a new world full of new experiences. Paula’s ...
- Early-Onset Dementia and Alzheimer’s Disease Have Tripled, Blue Cross Sayson February 27, 2020 at 3:29 pm
The rates of dementia and Alzheimer’s disease among commercially insured Americans aged 30 to 64 increased by 200% from 2013 to 2017, according to a new analysis by the Blue Cross Blue Shield ...
- Alzheimer's Disease Drug- Global Market Outlook 2020 to 2026 | Allergan plc AGN, Eisai Co., Ltd. ESALY, Daiichi Sankyo Companyon February 27, 2020 at 1:15 pm
This report on the global Alzheimer's Disease Drug Market Research Report 2019 is detailed research that helps answer business questions related to competitive intelligence, market analysis, and ...
- Berwyn biotech firm taking on Alzheimer’s disease receives $1.7M NIH granton February 27, 2020 at 8:13 am
Berwyn biotech firms gets $1.7M NIH grant to support development of a new drug candidate for the treatment of Alzheimer's and Parkinson's diseases.
- Blue Cross Plans Say Alzheimer’s Has Tripled Among Adults Ages 30 To 64on February 27, 2020 at 3:02 am
Early-onset dementia and Alzheimer’s disease jumped 200% among commercially insured Americans between the ages of 30 and 64 over a recent five-year period, a new analysis of Blue Cross and Blue Shield ...
- Early-Onset Dementia and Alzheimer's Diagnoses Spiked 373 Percent for Generation X and Millennialson February 27, 2020 at 3:00 am
/PRNewswire/ -- The number of commercially insured Americans age 30 to 64 diagnosed with early-onset dementia or Alzheimer's disease increased by 200% ...
- Delivering Crocetin across the Blood-Brain Barrier by Using γ-Cyclodextrin to Treat Alzheimer’s Diseaseon February 27, 2020 at 2:32 am
Crocetin (CRT) has shown various neuroprotective effects such as antioxidant activities and the inhibition of amyloid β fibril formation, and thus is a potential therapeutic candidate for Alzheimer’s ...
- Scientists find new way to save neurons in Alzheimer’s diseaseon February 26, 2020 at 8:34 am
Neurons die earlier than experts previously thought in Alzheimer’s disease, and stopping the process could prevent the disease from ever developing, finds a new study from Tokyo Medical and Dental ...
- Widowhood increases risk of Alzheimer's, study sayson February 26, 2020 at 8:16 am
Being a widow or widower may be a high risk factor for cognitive decline associated with beta amyloid and Alzheimer disease, a new study finds.
via Bing News